Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
One of the main clinical
2022-06-08

One of the main clinical issues of ABCB1, together with its impact on intestinal absorption, concerns its location at the BBB. Indeed, ABCB1 has been identified in the luminal side of endothelial cells and in the abluminal side of astrocyte endfeet processes of the CNS microvasculature [[36], [37],
-
The knowledge that piroxicam competes with
2022-06-07

The knowledge that piroxicam competes with ligands that bind to FPR may be of importance for a deeper understanding of the anti-inflammatory effects possessed by this NSAIDs. It has recently been reported that not only phagocytes but also platelets express FPR on their cell surface and that these re
-
br Discussion and concluding remarks FPR
2022-06-07

Discussion and concluding remarks FPR1 is considered to be a promising drug target for treating inflammatory and immunological diseases. Thus, natural compounds that could block and/or regulate FPR1 activity may be an important source of novel therapeutics for modulating inflammatory processes. H
-
To investigate an involvement of GPR and
2022-06-07

To investigate an involvement of GPR120 and GPR40 in the enhancement of cell motile activity of MG-63 cells, highly migratory (MG63-R7) Biotin-11-dUTP australia were established from MG-63 cells (Fig. 2A). The expression level of GPR120 gene was significantly higher in MG63-R7 cells than in MG-63 c
-
br Conclusion In summary a series of novel GPR agonists
2022-06-07

Conclusion In summary, a series of novel GPR40 agonists bearing phenylpropiolic ddhC motif with favorable metabolic stability were prepared and evaluated for their activities as GPR40 agonists. Among them, compound 9 was identified as a structurally distinct GPR40 agonist possessing potent activ
-
We then explored the possible mechanisms by which integrin w
2022-06-07

We then explored the possible mechanisms by which integrin α5β1 was involved in the PHEV proliferation process. Normally, the virus activates integrin and induces its downstream protein activation to promote its own invasion and proliferation. Human papillomavirus type 16 (HPV16) binds to heparan su
-
br Discussion This study dedicated to histamine H
2022-06-07

Discussion This study, dedicated to MRS 2578 mg H3 and H4 receptors, was carried out on superfused tissues preincubated with 3H-choline or 3H-noradrenaline; electrical stimulation was used to elicit quasi-physiological exocytotic release of the respective transmitter. Since inhibition of transm
-
The presence of the H receptor in humans was confirmed
2022-06-07

The presence of the H3 receptor in humans was confirmed approximately 25 years ago, and the receptor was successfully cloned in 1999 (Thurmond, 2010). The H3 receptor is unique, as it controls feedback of histamine release, particularly in the central nervous system, where it modulates neurotransmit
-
A second H R antagonist with benzamide based
2022-06-07

A second H3R antagonist with benzamide-based structure from Johnson & Johnson is JNJ-31001074, known as Bavisant and under chemical IUPAC name of (4-cyclopropylpiperazin-1-yl)-[4-(morpholin-4-ylmethyl)phenyl]methanone. It is a compound with molecular weight 329.44, HBA four, and MLogP 1.52 encompass
-
In first wave first generation
2022-06-07

In 2013, first-wave, first-generation drugs telaprevir and boceprevir was the first protease inhibitors (PIs) incorporated in Brazilian Clinical Guidelines for the treatment of patients infected with HCV APY29 australia 1. Based on this 2013 Clinical Guideline, telaprevir could be used for both naï
-
Measured physicochemical water parameters including conducti
2022-06-07

Measured physicochemical water parameters including conductivity, suspended solids and nutrient load along the studied sites (Table 1) were high compared to levels usually found in undisturbed rivers within Europe (Chapman and Kimstach, 1996). In particular conductivity, suspended solids and phospha
-
br Concluding remarks br Conflict of
2022-06-07

Concluding remarks Conflict of interest statement References and recommended reading Papers of particular interest, published within the period of review, have been highlighted as: Acknowledgements We thank all the present and former members in our laboratory for their contributions to
-
Two genes PATL and RASSF whose relationship
2022-06-07

Two genes (PATL2 and RASSF1), whose relationship to HIV infection had not previously been reported, were identified in this study. Although PATL2 and RASSF1 have been implicated in cell division and tumor suppression, respectively (Scheller et al., 2007, Rather et al., 2014, Liu et al., 2002), their
-
In conclusion we have identified ten
2022-06-07

In conclusion, we have identified ten novel GPCR genes and a pseudogene. Transcripts for GPR78, GPR81, GPR94, GPR95, GPR101, GPR103 and P2Y were detected in various CNS and peripheral tissues. Given the high levels of identity observed within paralogous oGPCR gene clusters, future efforts will likel
-
br Acknowledgements We thank the support of the National
2022-06-07

Acknowledgements We thank the support of the National Natural Science Foundation of China (NSFC) project 81501342 and support from the Disciplinary Group of Oncology and Immunology program of Xinxiang Medical University. Introduction First described as a new clinical entity in 1981, the Acqui
16233 records 435/1083 page Previous Next First page 上5页 431432433434435 下5页 Last page